Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (201-210 of 283) with videos related to

Pageof 29
Sort By:
Cancer Medicine|October 24, 2017
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimenAlaa M Ali, Daniel Weisel, Feng Gao, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 11, 2025
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodyKarthik Ramasamy, Ravi Vij, David Kuter, et al.
Blood Advances|July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)Alison R Walker, Guido Marcucci, Jun Yin, et al.
Future Oncology (London, England)|April 23, 2024
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myelomaPaula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Leukemia|August 30, 2024
IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myelomaJennifer Sun, Stefan Corradini, Feda Azab, et al.
Blood|August 1, 2020
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myelomaJagoda K Jasielec, Tadeusz Kubicki, Noopur Raje, et al.
The New England Journal of Medicine|February 10, 2023
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 25, 2017
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple MyelomaErik H van Beers, Martin H van Vliet, Rowan Kuiper, et al.
Oncogenesis|October 6, 2025
Investigation of lncRNA expression in newly diagnosed multiple myeloma reveals a LINC01432-CELF2 axis as an inhibitor of apoptosisRicha Mishra, Prasanth Thunuguntla, Dhanusha Duraiyan, et al.
British Journal of Haematology|July 22, 2025
Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOSNasheed M Hossain, Kwang Woo Ahn, Jinalben Patel, et al.
Pageof 29

Showing results (201-210 of 283) with videos related to

Sort By:
Pageof 29
Cancer Medicine|October 24, 2017
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimenAlaa M Ali, Daniel Weisel, Feng Gao, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 11, 2025
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodyKarthik Ramasamy, Ravi Vij, David Kuter, et al.
Blood Advances|July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)Alison R Walker, Guido Marcucci, Jun Yin, et al.
Future Oncology (London, England)|April 23, 2024
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myelomaPaula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Leukemia|August 30, 2024
IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myelomaJennifer Sun, Stefan Corradini, Feda Azab, et al.
Blood|August 1, 2020
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myelomaJagoda K Jasielec, Tadeusz Kubicki, Noopur Raje, et al.
The New England Journal of Medicine|February 10, 2023
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 25, 2017
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple MyelomaErik H van Beers, Martin H van Vliet, Rowan Kuiper, et al.
Oncogenesis|October 6, 2025
Investigation of lncRNA expression in newly diagnosed multiple myeloma reveals a LINC01432-CELF2 axis as an inhibitor of apoptosisRicha Mishra, Prasanth Thunuguntla, Dhanusha Duraiyan, et al.
British Journal of Haematology|July 22, 2025
Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOSNasheed M Hossain, Kwang Woo Ahn, Jinalben Patel, et al.
Pageof 29